Related Experiment Videos
Ceftazidime therapy for serious infections
Abstract:
Thirty-two episodes of severe infection in 23 patients were treated with parenteral ceftazidime: 96% of the infections were cured or improved. Of 15 chest infections in cystic fibrosis patients, 14 responded satisfactorily to treatment, including 9 cases where Pseudomonas aeruginosa and 7 cases where Staphylococcus aureus was a pathogen. All seven cases of peritonitis in peritoneal dialysis patients were cured or improved. Other infections that responded to treatment were urinary tract infections (3), septicaemias (2), wound infections (2), acute bronchitis (2) and cholangitis (1). Ceftazidime was shown to produce good blood and peritoneal dialysis fluid levels and to penetrate into sputum. Adverse effects were few and not serious.
Insights
Parenteral ceftazidime effectively treated severe infections in 23 patients, achieving a 96% cure or improvement rate. This included successful outcomes in cystic fibrosis patients and those with peritonitis, demonstrating ceftazidime
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Severe infections pose significant treatment challenges.
- Ceftazidime is a third-generation cephalosporin antibiotic.
- Evaluating antibiotic efficacy in diverse patient populations is crucial.
Purpose of the Study:
- To assess the efficacy and safety of parenteral ceftazidime in treating severe infections.
- To evaluate treatment outcomes in specific patient groups, including cystic fibrosis and peritoneal dialysis patients.
- To determine ceftazidime's pharmacokinetic profile in blood, peritoneal dialysis fluid, and sputum.
Main Methods:
- Retrospective analysis of 32 severe infection episodes in 23 patients treated with ceftazidime.
- Categorization of infections by type and patient population.
- Monitoring of clinical response, pathogen identification, and adverse effects.
Main Results:
- 96% of all severe infections showed clinical cure or improvement.
- 14 of 15 chest infections in cystic fibrosis patients responded well, with identified pathogens including Pseudomonas aeruginosa and Staphylococcus aureus.
- All 7 cases of peritonitis in peritoneal dialysis patients were successfully treated.
- Good drug levels were achieved in blood and peritoneal dialysis fluid, with sputum penetration observed.
- Adverse effects were minimal and not severe.
Conclusions:
- Parenteral ceftazidime demonstrates high efficacy in treating a range of severe infections.
- The antibiotic is particularly effective in cystic fibrosis patients and those with peritonitis.
- Ceftazidime exhibits favorable pharmacokinetic properties, supporting its use in these clinical scenarios.